This trial is evaluating whether Contrast enhanced ultrasound with Lumason will improve 1 primary outcome in patients with Carcinoma, Renal Cell. Measurement will happen over the course of first 6 months.
This trial requires 40 total participants across 2 different treatment groups
This trial involves 2 different treatments. Contrast Enhanced Ultrasound With Lumason is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
Carcinoma, renal cell, is likely to be caused by a combination of multiple environmental factors. Since the risk of developing carcinoma, renal cell, is also influenced by genetics, environmental factors may be linked. These factors may not be neatly separated from one another. A multi-centered study needs to establish the best approach to understanding the combined effects of all these factors in the risk of developing carcinoma, renal cell.
Rare cancers often involve major organ systems and respond only slowly to conventional treatment. The optimal and most appropriate treatment for these cancers may vary between disease subtypes. For aggressive forms of renal cell cancer, complete cystectomy followed by adjuvant chemotherapy is often prescribed. Surgical removal of the bladder followed by partial cystectomy after completion of adjuvant chemotherapy is particularly recommended in the setting of aggressive transitional cell carcinoma.
Carcinoma, renal cell is a cancer of epithelial organs. The exact incidence of renal carcinoma is unknown. It may be an asymptomatic disease, rarely painful in men. Rarely it is detected at the stage of renal cortical metastasis. Diagnosis is most often made by pathological examination of the kidney. Most common types of renal cell carcinoma are transitional cell carcinoma, clear cell carcinoma and adenocarcinoma. Testicular cancer tends to present as undescended scrotum, painful penile swelling and flank enlargement.
The number of persons with kidney carcinoma in each state is underestimated even when the data are adjusted for the population rate and the incidence of ESRD. Estimates from a population-based study of Medicare data indicate the incidence of renal cell carcinoma is approximately 25 times higher than the incidence of ESRD that would result from a population prevalence of 7.4 million adults with ESRD.
The overall survival rate of patients with carcinoma, renal cell is very low. Treatment of the metastatic site does not enhance the outcome in these patients. Local therapy achieves a survival improvement of 13.6 months only in patients with a synchronous metastatic disease. We can conclude the curability of carcinomas, renal cell must be considered in adjuvant treatment.
The use of bolus-tracking CEUS is a safe, noninvisible and highly useful procedure for the performance of dynamic imaging and the diagnosis of malignant and benign lesions and their differential with renal cell carcinoma, both in the kidneys and in the upper abdominal and pelvic region. CEUS seems to be an excellent tool for detecting renal cell carcinoma, as well as metastasizing and nonmetastasizing metastatic lesions, which may be detected by dynamic imaging. Further prospective and larger-patient studies are required.
Results from a recent clinical trial of this study indicate that the mortality for renal cell carcinoma remains at high level. This discrepancy cannot be attributed exclusively to the demographic and clinicopathological features of patients with renal cell carcinoma. Results from a recent clinical trial suggests that more research is needed to investigate the pathogenesis contributing to the higher mortality of patients with renal cell carcinoma, and to implement appropriate interventions to improve the clinical outcomes of these patients.
Although this information is important and is needed, no one is fully aware of the prognosis of the treatment they receive for RCC. A patient's survival rate is dependent on their treatment and tumour type.
CEUS can be used as non invasive tool with high specificity to detect malignant pathologies, in particular malignant renal tumors. This application is very simple to perform and can be of great clinical value, as malignant tumors are frequently vascularized.
Ultrasonic contrast agent based sonomagrams provide important information on tumor architecture, blood flow and vessel anatomy. The contrast enhanced sonographic appearance of the lesions in the kidney has been demonstrated to provide an initial assessment of renal vascularity and has the potential to be used as an adjunct to CT-guided intervention.
Despite its growing presence as a complementary examination in endourology, CE-US is not typically used, nor is it used in combination with any other treatment, in most clinical practice at the present time because its value has not been demonstrated in the absence of treatment.